Mesoblast wins long-await­ed ap­proval for cell ther­a­py

Mesoblast’s stock surged on Thurs­day af­ter the com­pa­ny won FDA ap­proval for its twice-re­ject­ed graft-ver­sus-host dis­ease ther­a­py.

Remestem­cel-L is the first mes­enchy­mal stro­mal cell ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER